RxDoctor Payments Data

Erin Vaughan

Family · Houston, TXNPI 1386099315

Payments from drug & device makers

$8,054in general payments, 2019–2025

Across 438 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$862
  • Amgen$840
  • Lilly USA, LLC$780
  • Novo Nordisk$680
  • Supernus Pharmaceuticals, Inc.$458
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$8,054100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,054 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$40,870
Medicare patients
123
Services billed
423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$40,842
FarxigaDapagliflozin Propanediol11$9,804
Venlafaxine Hcl ErVenlafaxine Hcl18$3,381
SynthroidLevothyroxine Sodium24$1,979
Bupropion XlBupropion Hcl49$1,707
Rosuvastatin Calcium98$1,527
Levothyroxine Sodium106$987
Atorvastatin Calcium83$845
Estradiol17$806
Losartan Potassium66$744
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide16$691
Olmesartan Medoxomil16$529
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst28$527
Amlodipine Besylate59$453
Duloxetine Hcl25$423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$680$40,84230 claims
AstraZenecaFarxiga$862$9,80411 claims
AbbVieSynthroid$1,072$1,97924 claims
Almatica Pharma LLCSertraline Hcl$39$31321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →